Advertisement

International Journal of Hematology

, Volume 107, Issue 2, pp 211–221 | Cite as

Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan

  • Tatsunori Goto
  • Takashi Tanaka
  • Masashi Sawa
  • Yasunori Ueda
  • Hiroatsu Ago
  • Shigeru Chiba
  • Heiwa Kanamori
  • Akinori Nishikawa
  • Masaharu Nougawa
  • Kazuteru Ohashi
  • Hirokazu Okumura
  • Mitsune Tanimoto
  • Takahiro Fukuda
  • Naomi Kawashima
  • Tomonori Kato
  • Kazuya Okada
  • Koji Nagafuji
  • Shin-ichiro Okamoto
  • Yoshiko Atsuta
  • Masayuki Hino
  • Junji Tanaka
  • Koichi Miyamura
Original Article

Abstract

The Japan Marrow Donor Program (JMDP) has facilitated unrelated peripheral blood stem cell transplantation (URPBSCT) since 2010. We conducted a prospective multicenter observational study to evaluate the feasibility of such transplantation. Between 2011 and 2014, 51 patients underwent URPBSCT from 8/8 allele-matched donors for hematological malignancies. The median age of the patients was 50 years; 21 had high-risk disease. Myeloablative conditioning regimens were used in 31 patients, and tacrolimus based graft-versus-host disease (GVHD) prophylaxis was used for all patients. The cumulative rate of engraftment was 96%. With a median follow-up period of 610 days for survivors, 100-day and 1-year overall survival rates were 86 and 59%, respectively. The cumulative incidence of non-relapse mortality and relapse at 1 year were 14 and 35%, respectively. The incidence of grade II to IV acute GVHD at 100 days and extensive type of chronic GVHD at 1 year were 25 and 32%, respectively. The probability of overall survival was comparable with that of bone marrow transplantation from HLA matched-unrelated donors in Japan, although the incidence of chronic GVHD was higher. Further follow-up with more patients is clearly warranted to establish the optimal use of URPBSCT together with the approaches of minimizing chronic GVHD.

Keywords

Peripheral blood stem cell Allogeneic hematopoietic cell transplantation Unrelated donor 

Notes

Acknowledgements

This work was supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan (H26-Nanchi- (Immunology)-Ippan-101 to K.M.). The authors thank all the staff members of the collaborating institutes of the Japan Marrow Donor Program for their assistance and cooperation. This work is dedicated to Yoshihisa Kodera, MD and Mine Harada, MD who was providing oversight during the conduct of this study. The authors also would like to thank the following institutes for enrolling a patient in this study: the Department of Hematology at Nagasaki University Hospital, the Department of Hematology and Oncology at Nagoya University Graduate School of Medicine, the Department of Hematology and Rheumatology at Tohoku University Graduate School of Medicine, the Department of Medicine and Biosystemic Science at Kyushu University Faculty of Medicine, the Department of Hematology and Oncology at Tokai University School of Medicine, the Department of Hematology at Shinko Hospital, and the Department of Hematology at Osaka Red Cross Hospital. We also thank the members of this study group, Takanori Teshima, MD, Tetsuya Nishida, MD, and Minako Iida, MD; the protocol committee members, Masami Inoue, MD, Onishi Yasushi, MD, Yoshinobu Kanda, MD, Sung-Won Kim, MD and Yasuo Morishima, MD.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

References

  1. 1.
    Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–100.CrossRefPubMedGoogle Scholar
  2. 2.
    Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87.CrossRefGoogle Scholar
  3. 3.
    Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, et al. The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transpl. 2010;16:253–62.CrossRefGoogle Scholar
  4. 4.
    Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Morton J, Hutchins C, Durrant S. Granulocyte—colony-stimulating factor (G-CSF)—primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF–mobilized peripheral blood stem cells. Blood. 2001;98:3186–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Nagafuji K, Matsuo K, Teshima T, S-i Mori, Sakamaki H, Hidaka M, et al. Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. Int J Hematol. 2010;91:855–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87.CrossRefGoogle Scholar
  11. 11.
    Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Morishima Y, Morishita Y, Tanimoto M, Ohno R, Saito H, Horibe K, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252–6.PubMedGoogle Scholar
  13. 13.
    Oh H, Loberiza FR Jr, Zhang MJ, Ringden O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, et al. Graft-versus-host disease after HLA-matched sibling bone marrow or peripheral blood stem cell transplantation: comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transpl. 2016;22:744–51.CrossRefGoogle Scholar
  15. 15.
    Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9.CrossRefGoogle Scholar
  16. 16.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.Google Scholar
  17. 17.
    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.CrossRefPubMedGoogle Scholar
  18. 18.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.CrossRefGoogle Scholar
  19. 19.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  21. 21.
    Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep. 1985;69:1–3.PubMedGoogle Scholar
  22. 22.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  23. 23.
    Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute Leukemia. Biol Blood Marrow Transpl. 2016;22:330–8.CrossRefGoogle Scholar
  24. 24.
    Tanaka M, Miyamura K, Terakura S, Imai K, Uchida N, Ago H, et al. Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years. Biol Blood Marrow Transpl. 2015;21:517–25.CrossRefGoogle Scholar
  25. 25.
    Young JA, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transpl. 2016;22:359–70.CrossRefGoogle Scholar
  26. 26.
    Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2:1583–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl. 2006;12:560–5.CrossRefGoogle Scholar
  28. 28.
    Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transpl. 2016;22:1037–42.CrossRefGoogle Scholar
  30. 30.
    Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transpl. 2013;48:243–8.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Tatsunori Goto
    • 1
  • Takashi Tanaka
    • 2
  • Masashi Sawa
    • 3
  • Yasunori Ueda
    • 4
  • Hiroatsu Ago
    • 5
  • Shigeru Chiba
    • 6
  • Heiwa Kanamori
    • 7
  • Akinori Nishikawa
    • 8
  • Masaharu Nougawa
    • 9
  • Kazuteru Ohashi
    • 10
  • Hirokazu Okumura
    • 11
  • Mitsune Tanimoto
    • 12
  • Takahiro Fukuda
    • 2
  • Naomi Kawashima
    • 1
  • Tomonori Kato
    • 3
  • Kazuya Okada
    • 4
  • Koji Nagafuji
    • 13
  • Shin-ichiro Okamoto
    • 14
  • Yoshiko Atsuta
    • 15
  • Masayuki Hino
    • 16
  • Junji Tanaka
    • 17
  • Koichi Miyamura
    • 1
  1. 1.Department of HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan
  2. 2.Division of Hematopoietic Stem Cell TransplantationNational Cancer Center HospitalTokyoJapan
  3. 3.Department of Hematology and OncologyAnjo Kosei HospitalAnjoJapan
  4. 4.Department of Hematology/OncologyKurashiki Central HospitalKurashikiJapan
  5. 5.Division of Hematology and OncologyShimane Prefectural Central HospitalMatsueJapan
  6. 6.Department of Hematology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  7. 7.Department of HematologyKanagawa Cancer CenterYokohamaJapan
  8. 8.Department of Hematology/OncologyWakayama Medical UniversityWakayamaJapan
  9. 9.Division of HematologyJapanese Red Cross Society Wakayama Medical CenterWakayamaJapan
  10. 10.Division of HematologyTokyo Metropolitan Cancer and Infectious Disease Center Komagome HospitalTokyoJapan
  11. 11.Hematology DepartmentToyama Prefectural Central HospitalToyamaJapan
  12. 12.Department of Hematology and OncologyOkayama University HospitalOkayamaJapan
  13. 13.Department of Hematology and Oncology, School of MedicineKurume UniversityKurumeJapan
  14. 14.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  15. 15.Japanese Data Center for Hematopoietic Cell TransplantationNagoyaJapan
  16. 16.Hematology, Graduate School of MedicineOsaka City UniversityOsakaJapan
  17. 17.Department of HematologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations